Major Events - Kuaishou-W (01024) strongly condemns illegal activities related to black and gray industries, has reported to law enforcement and relevant authorities [1] - Sihon Pharmaceutical (02096) receives clinical trial approval for SIM0610 (EGFR/cMET bispecific antibody-drug conjugate) from the National Medical Products Administration [1] - Sinopec Engineering (02386) plans to acquire 100% equity of East China Pipeline Design Institute [1] - Yanda Pharmaceutical (00512) introduces the world's first epinephrine nasal spray for treating severe allergic reactions [1] - Valiant Pharmaceuticals-B (09887) reports the first subject has been dosed in Phase I trial of LBL-047 [1] - Xinyi Energy (03868) intends to acquire 100% equity of Jinzhai Xinyi Wind Power for 62 million yuan [1] - Zhongneng Holdings (00228) plans to receive a premium of approximately 9.03% for a full acquisition offer, with resumption of trading on December 24 [1] Operating Performance - Xipuni (02583) issues a profit warning, expecting annual net profit to increase year-on-year [1] - AEON CREDIT (00900) reports a profit of 353 million HKD for the first three quarters, an increase of 28.11% year-on-year [1] - New Fire Technology Holdings (01611) anticipates an annual net loss not exceeding 10 million HKD [1]